Disease · MONDO_0810000

choroidal neovascularization

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. choroidal neovascularization. Diseases, record MONDO_0810000. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0810000

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: choroidal neovascularization; Open Targets
Open Targets ID: MONDO_0810000; Open Targets
MeSH: D020256; MeSH
Highest stage of its drugs: Approval, for 2 of its 34 drugs, from EMA Human Drugs and PMDA; Open Targets

Drugs34

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
RANIBIZUMAB	CHEMBL1201825	Antibody	Approval	EMA Human Drugs	51	46	46	Drugs and targets
AFLIBERCEPT	CHEMBL1742982	Protein	Approval	EMA Human Drugs and PMDA	26	14	14	Drugs and targets
VERTEPORFIN	CHEMBL5314346	Small molecule	Phase 3	ClinicalTrials.gov	20	20	20	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 3	ClinicalTrials.gov	18	18	18	Drugs and targets
CONBERCEPT	CHEMBL2108313	Protein	Phase 3	ClinicalTrials.gov	5	5	4	Drugs and targets
FARICIMAB	CHEMBL4297750	Antibody	Phase 3	ClinicalTrials.gov	3	2	2	Drugs and targets
ANECORTAVE ACETATE	CHEMBL2106613	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
BROLUCIZUMAB	CHEMBL3707357	Antibody	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
TRIAMCINOLONE ACETONIDE	CHEMBL1504	Small molecule	Phase 2/3	ClinicalTrials.gov	5	5	4	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Phase 2	ClinicalTrials.gov	8	7	6	Drugs and targets

1 to 10 of 34

See all 34 drugs

Targets35

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	12	Glucocorticoid receptor agonist	Phase 2/3	https://conductscience.org/library/genes/2908	Drugs and targets
VEGFA	Vascular endothelial growth factor A, long form	7	Vascular endothelial growth factor A antagonist; Vascular endothelial growth factor A inhibitor	Approval	https://conductscience.org/library/genes/7422	Drugs and targets
PGF	Placenta growth factor	2	Placenta growth factor inhibitor	Approval	https://conductscience.org/library/genes/5228	Drugs and targets
TNF	Tumor necrosis factor	2	TNF-alpha inhibitor	Phase 2	https://conductscience.org/library/genes/7124	Drugs and targets
ABL1	Bcr/Abl fusion protein	1	Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor	Phase 1	https://conductscience.org/library/genes/25	Drugs and targets
ANGPT2	Angiopoietin-2	1	Angiopoietin-2 inhibitor	Phase 3	https://conductscience.org/library/genes/285	Drugs and targets
BCR	Bcr/Abl fusion protein	1	Bcr/Abl fusion protein inhibitor	Phase 1	https://conductscience.org/library/genes/613	Drugs and targets
C3	Complement C3	1	Complement C3 inhibitor	Phase 1	https://conductscience.org/library/genes/718	Drugs and targets
FLT1	VEGFR1 mRNA	1	VEGFR1 mRNA rnai inhibitor	Phase 2	https://conductscience.org/library/genes/2321	Drugs and targets
ITGA5	Integrin alpha-5/beta-1	1	Integrin alpha-5/beta-1 antagonist	Phase 1	https://conductscience.org/library/genes/3678	Drugs and targets

1 to 10 of 35

See all 35 targets

Trials95

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02307682	Efficacy and Safety of RTH258 Versus Aflibercept - Study 1	Phase 3	1,775	2019-10-31	Neovascular Age-Related Macular Degeneration, Choroidal Neovascularization	AFLIBERCEPT, BROLUCIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00637377	Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)	Phase 3	1,240	2012-01-23	Macular Degeneration	AFLIBERCEPT, RANIBIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00891735	A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)	Phase 3	1,097	2013-01-18	Age-related Macular Degeneration	RANIBIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02434328	Efficacy and Safety of RTH258 Versus Aflibercept - Study 2	Phase 3	1,048	2019-10-31	Neovascular Age-Related Macular Degeneration, Choroidal Neovascularization	AFLIBERCEPT, BROLUCIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00379795	An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVO	Not applicable	853	2012-01-13	Choroidal Neovascularization, Age-related Macular Degeneration	RANIBIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT01442064	An Extension Study to Evaluate Safety and Tolerability of Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion (Cohort 2)	Not applicable	608	2012-01-10	Macular Edema, Retinal Vein Occlusion	RANIBIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00331864	SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration	Phase 3	531	2011-01-04	Age Related Macular Degeneration, Choroidal Neovascularization	RANIBIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT01922102	Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia	Phase 3	457	2019-06-24	Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)	RANIBIZUMAB, VERTEPORFIN	Its record names the disease	ClinicalTrials.gov
NCT00436553	Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization	Phase 3	321	2011-04-19	Macular Degeneration, Choroidal Neovascularization	RANIBIZUMAB, VERTEPORFIN	Its record names the disease	ClinicalTrials.gov
NCT01217944	Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia	Phase 3	277	2013-10-18	Pathological Myopia	RANIBIZUMAB, VERTEPORFIN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 95

See all 95 trials

Comparisons in its trials13

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Brolucizumab 6mg vs Aflibercept 2mg: deaths from any cause	4 of 370	7 of 369	739	NCT02434328	Trial comparisons
Brolucizumab 6mg vs Aflibercept 2mg: serious adverse events	79 of 370	89 of 369	739	NCT02434328	Trial comparisons
Ranibizumab Non-ANCHOR vs Ranibizumab ANCHOR: serious adverse events	80 of 513	4 of 18	531	NCT00331864	Trial comparisons
Verteporfin + Ranibizumab vs Ranibizumab: serious adverse events	25 of 122	28 of 133	255	NCT00433017	Trial comparisons
Ranibizumab vs Sham Control: Number of Participants With Requirement for Rescue Treatment at Month 1	0 of 119	1 of 58	177	NCT01840410	Trial comparisons
Group I vs Group II: deaths from any cause	0 of 30	0 of 30	60	NCT00527475	Trial comparisons
Group I vs Group II: serious adverse events	0 of 30	0 of 30	60	NCT00527475	Trial comparisons
ICON-1 Maintenance Therapy vs ICON-1 Combination Therapy: deaths from any cause	0 of 7	0 of 8	15	NCT03452527	Trial comparisons
ICON-1 Maintenance Therapy vs ICON-1 Combination Therapy: serious adverse events	2 of 7	1 of 8	15	NCT03452527	Trial comparisons
Ranibizumab Dose A vs Ranibizumab Dose B: Number of Subjects Avoiding 15 or More Letter Loss of Best Corrected Visual Acuity From Baseline to 12 Months on an Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Chart Measured at 4 Meters.	5 of 5	2 of 2	7	NCT00363168	Trial comparisons

1 to 10 of 13

See all 13 comparisons in its trials

Papers from its trials72

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
35822428	RESULT	1	PubMed
25012926	RESULT	1	PubMed
24084500	RESULT	1	PubMed
23084240	RESULT	1	PubMed
22382503	RESULT	1	PubMed
21826150	RESULT	1	PubMed
21358461	RESULT	1	PubMed
21232078	RESULT	1	PubMed
20827138	RESULT	1	PubMed
20163368	RESULT	1	PubMed

1 to 10 of 72

See all 72 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0810000

GET https://conductscience.org/api/diseases/v1/MONDO_0810000/drugs?page=2

API reference For AI assistants